Resilience is set to acquire AstraZeneca's commercial-scale drug manufacturing plant outside Cincinnati next year as part of a new long-term biomanufacturing partnership between the two companies.
Resilience is set to acquire AstraZeneca's commercial-scale drug manufacturing plant outside Cincinnati next year as part of a new long-term biomanufacturing partnership between the two companies.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In